Detalhe da pesquisa
1.
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Cancer
; 130(11): 1940-1951, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288862
2.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 381(25): 2391-2402, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562799
3.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol
; 166(1): 36-43, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550709
4.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol
; 22(5): 632-642, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862001
5.
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1721-1731, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715071
6.
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Gynecol Oncol
; 163(2): 392-397, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34548162
7.
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol
; 163(1): 41-49, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34353615
8.
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 150(1): 119-126, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29778506
9.
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 147(2): 283-290, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802766
10.
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 144(3): 459-467, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089376
11.
Endometrial carcinoma: The perioperative and long-term outcomes of robotic surgery in the morbidly obese.
J Surg Oncol
; 114(7): 884-887, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27566529
12.
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Gynecol Oncol
; 139(2): 228-35, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26383827
13.
Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma.
BMC Clin Pathol
; 15: 17, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412982
14.
Pathway index models for construction of patient-specific risk profiles.
Stat Med
; 32(9): 1524-35, 2013 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-23074142
15.
Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies.
Brachytherapy
; 22(5): 630-639, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37394350
16.
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.
JCO Clin Cancer Inform
; 7: e2200103, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608308
17.
Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14, 958.
Cancers (Basel)
; 14(10)2022 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35626175
18.
Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance.
Cancers (Basel)
; 14(4)2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205706
19.
GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.
Clin Cancer Res
; 27(20): 5536-5545, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34326131
20.
Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Cancer Res
; 81(20): 5336-5352, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380633